Microbiome therapies pipeline features 260 drugs under evaluation across different phases of development, By Roots Analysis

Manufacturing live biotherapeutic products is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs.

• An assessment of microbiome contract manufacturing capability in different regions, based on a number of relevant parameters, such as number of CMOs, number of completed / active / planned clinical trials, number of patients enrolled, number of manufacturing facilities, number of companies offering API / FDF manufacturing, number of companies having capabilities for preclinical / clinical / commercial manufacturing, number of companies dedicated to aerobic / anaerobic fermentation, installed manufacturing capacity, and number of in-house players.
• A list of nearly 50 microbiome-focused drug developers that are anticipated to partner with contract manufacturers and have been shortlisted on the basis of parameters, such as developer strength (which takes into account the company's size and its experience in this field), company's pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and the availability of in-house manufacturing capabilities.
• A detailed clinical trial analysis of more than 150 completed, ongoing and planned studies of various microbiome therapeutics sponsored by both industry and non-industry players; it highlights prevalent trends across various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, trial recruitment status, study design and trial focus, highlighting leading sponsors (in terms of number of trials conducted), type of organization, popular therapeutic areas, and regional distribution of trials.
• An estimate of the overall, installed capacity for manufacturing of microbiome therapeutics, taking into consideration the capabilities of various stakeholders, based on data gathered via secondary and primary research; it presents the distribution of available capacity in terms of quantity of microbiome therapeutics produced (in liters, per year), across important market segments, such as company size (small-sized, mid-sized and large companies), scale of operation (clinical and commercial), and key geographical regions (North America, Europe and Asia-Pacific and rest of the world).

 

To order this 300+ page report, which features 140+ figures and 125+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html

 

The USD 300 million (by 2030) financial opportunity within the microbiome contract manufacturing market has been analysed across the following segments:

• Type of Product Manufactured
• Active Pharmaceutical Ingredients (APIs)
• Finish Drug Formulations (FDFs)

 

• Type of Type of Formulation
• Solid Formulations
• Oral Liquids
• Injectables
• Others

 

• Scale of Operation
• Clinical
• Commercial

 

• Company Size
• Small-sized
• Mid-sized
• Large

 

• Key Geographical Regions
• North America
• Europe
• Asia-Pacific and Rest of the World

 

The Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

• Bristol Myers Squibb
• GlaxoSmithKline
• Incyte
• Novartis
• Trillium Therapeutics

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction
 

4. Market Landscape
 

5. Company Profiles
 

6. Regional Capability Analysis
 

7. Likely Partner Analysis
 

8. Clinical Trial Analysis
 

9. Capacity Analysis
 

10. Demand Analysis
 

11. Make versus Buy Decision Making Framework
 

12. Microbiome related initiatives of Big Pharmaceutical Players
 

13. Market Forecast
 

14. Conclusion

 

15. Executive Insights

 

16. Appendix 1: Tabulated Data

 

17. Appendix 2: List of Companies and Organizations

 

18. Appendix 3: List of Probiotic Supplement Contract Manufacturers and       

Microbial Contract Service Providers

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]